Emerging drug target in pancreatic cancer

placing Sirtuin 1 on the canvas

Marc Giry Laterriere, Andreia V. Pinho, Nils Eling, Lorraine Chantrill, Ilse Rooman*

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

Original languageEnglish
Pages (from-to)463-468
Number of pages6
JournalCurrent Cancer Drug Targets
Volume15
Issue number6
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Keywords

  • Chemotherapy
  • Deleted in breast cancer 1
  • Genomic
  • Mutation
  • Pancreas
  • Personalized medicine
  • Sirtuin 1

Fingerprint Dive into the research topics of 'Emerging drug target in pancreatic cancer: placing Sirtuin 1 on the canvas'. Together they form a unique fingerprint.

  • Cite this